Twenty years on: The impact of fragments on drug discovery

Nature Reviews Drug Discovery

Volumn 15, Issue 9, 2016, Pages 605-619

  Erlanson, Daniel A ^a   Fesik, Stephen W ^b   Hubbard, Roderick E ^c,d   Jahnke, Wolfgang ^e   Jhoti, Harren ^f  

^a Carmot Therapeutics Inc   (United States)

^b VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF YORK   (United Kingdom)

^d Vernalis PLC   (United Kingdom)

^e NOVARTIS PHARMA AG   (Switzerland)

^f ASTEX PHARMACEUTICALS   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

1 CYCLOPROPYL 3 [3 (5 MORPHOLINOMETHYL 1H BENZIMIDAZOL 2 YL) 1H PYRAZOL 4 YL]UREA; 4 AMINO N [1 (4 CHLOROPHENYL) 3 HYDROXYPROPYL] 1 (7H PYRROLO[2,3 D]PYRIMIDIN 4 YL) 4 PIPERIDINECARBOXAMIDE; 4 [4 (4' CHLORO 2 BIPHENYLYLMETHYL) 1 PIPERAZINYL] N [4 [3 DIMETHYLAMINO 1 (PHENYLTHIOMETHYL)PROPYLAMINO] 3 NITROBENZENESULFONYL]BENZAMIDE; ABL 001; ABT 518; ASPARTIC PROTEINASE INHIBITOR; ASTX 660; AT 13148; AT 7519; AZD 3293; AZD 3839; AZD 5099; BCL 201; CYCLIC AMP DEPENDENT PROTEIN KINASE; CYCLIN DEPENDENT KINASE INHIBITOR; DG 051; ERDAFITINIB; INDEGLITAZAR; LUMINESPIB; LY 2886721; N [2 [4 (1 METHYL 4 PIPERIDINYL) 1 PIPERAZINYL] 2 OXO 1 PHENYLETHYL] 1H INDOLE 6 CARBOXAMIDE; NAVITOCLAX; ONALESPIB; PROTEIN INHIBITOR; PROTEIN KINASE B INHIBITOR; SGX 393; UNCLASSIFIED DRUG; UNINDEXED DRUG; VEMURAFENIB; VENETOCLAX; VERUBECESTAT; MOLECULAR LIBRARY; PEPTIDE FRAGMENT; PEPTIDE LIBRARY;

AFFINITY CHROMATOGRAPHY; BINDING AFFINITY; BIOPHYSICS; DRUG APPROVAL; DRUG BINDING SITE; DRUG DESIGN; DRUG INFORMATION; DRUG RESEARCH; DRUG SCREENING; DRUG STRUCTURE; DRUG TARGETING; HIGH THROUGHPUT SCREENING; HUMAN; MOLECULAR MECHANICS; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROCESS OPTIMIZATION; PROTEIN PROTEIN INTERACTION; REVIEW; SOLID TUMOR; STRUCTURE ACTIVITY RELATION; SURFACE PLASMON RESONANCE; X RAY CRYSTALLOGRAPHY; BIOLOGY; CLINICAL TRIAL (TOPIC); DRUG DEVELOPMENT; MOLECULAR LIBRARY; PEPTIDE LIBRARY; PROTEIN CONFORMATION; TRENDS;

CLINICAL TRIALS AS TOPIC; COMPUTATIONAL BIOLOGY; DRUG DISCOVERY; HIGH-THROUGHPUT SCREENING ASSAYS; HUMANS; PEPTIDE FRAGMENTS; PEPTIDE LIBRARY; PROTEIN CONFORMATION; SMALL MOLECULE LIBRARIES;

EID: 84978474564     PISSN: 14741776     EISSN: 14741784     Source Type: Journal    
DOI: 10.1038/nrd.2016.109     Document Type: Review

References (110)

1. Macarron, R., et al. Impact of high-Throughput screening in biomedical research. Nat. Rev. Drug Discov. 10, 188-195 (2011
2. Barker, A., Kettle, J. G., Nowak, T., & Pease, J. E. Expanding medicinal chemistry space. Drug Discov. Today 18, 298-304 (2013
3. McGovern, S. L., Caselli, E., Grigorieff, N., & Shoichet, B. K. A common mechanism underlying promiscuous inhibitors from virtual and high-Throughput screening. J. Med. Chem. 45, 1712-1722 (2002
4. Irwin, J. J., et al. An aggregation advisor for ligand discovery. J. Med. Chem. 58, 7076-7087 (2015
5. Bohacek, R. S., McMartin, C., & Guida, W. C. The art and practice of structure-based drug design: a molecular modeling perspective. Med. Res. Rev. 16, 3-50 (1996
6. Ruddigkeit, L., van Deursen, R., Blum, L. C., & Reymond, J. L. Enumeration of 166 billion organic small molecules in the chemical universe database GDB 17. J. Chem. Inform. Mod. 52, 2864-2875 (2012
7. Doak, B. C., Morton, C. J., Simpson, J. S., & Scanlon, M. J. Design and evaluation of the performance of an NMR screening fragment library. Aus. J. Chem. 66, 1465-1472 (2013
8. Ferenczy, G. G., & Keseru, G. M. How are fragments optimized? A retrospective analysis of 145 fragment optimizations. J. Med. Chem. 56, 2478-2486 (2013
9. Hann, M. M., Leach, A. R., & Harper, G. Molecular complexity and its impact on the probability of finding leads for drug discovery. J. Chem. Inf. Comput. Sci. 41, 856-864 (2001
10. Leach, A. R., & Hann, M. M. Molecular complexity and fragment-based drug discovery: ten years on. Curr. Opin. Chem. Biol. 15, 489-496 (2011
11. Hann, M. M. Molecular obesity, potency and other addictions in drug discovery. Med. Chem. Commun. 2, 349-255 (2011
12. Leeson, P. D., & St Gallay, S. A. The influence of the ?organizational factor? on compound quality in drug discovery. Nat. Rev. Drug Discov. 10, 749-765 (2011
13. Young, R. J. in Tactics in Contemporary Drug Design. Vol. 9 (ed. Meanwell, N. A.) 1-68 (Springer-Verlag Berlin Heidelberg, 2014
14. Jencks, W. P. On the attribution and additivity of binding energies. Proc. Nat. Acad. Sci. USA 78, 4046-4050 (1981
15. Shuker, S. B., Hajduk, P. J., Meadows, R. P., & Fesik, S. W. Discovering high-Affinity ligands for proteins: SAR by NMR. Science 274, 1531-1534 (1996
16. Hajduk, P. J., et al. Discovery of potent nonpeptide inhibitors of stromelysin using SAR by NMR. J. Am. Chem. Soc. 119, 5818-5827 (1997
17. Erlanson, D. A., & Jahnke, W. (eds) Fragment-based Drug Discovery: Lessons and Outlook. Vol. 67 (Wiley-VCH, 2016
18. Harner, M. J., Frank, A. O., & Fesik, S. W. Fragment-based drug discovery using NMR spectroscopy. J. Biol. NMR 56, 65-75 (2013
19. Wang, F., & Fesik, S. W. in Fragment-based Drug Discovery: Lessons and Outlook. Vol. 67 (eds Erlanson, D. A., & Jahnke, W.) 371-390 (Wiley-VCH, 2016
20. Keseru, G. M., et al. Design principles for fragment libraries: maximizing the value of learnings from Pharma fragment based drug discovery (FBDD) programs for use in academia. J. Med. Chem. http://dx.doi.org/10.1021/acs.jmedchem.6b00197 (2016
21. Congreve, M., Carr, R., Murray, C., & Jhoti, H. A ?rule of three? for fragment-based lead discovery? Drug Discov. Today 8, 876-877 (2003
22. Jhoti, H., Williams, G., Rees, D. C., & Murray, C. W. The ?rule of three? for fragment-based drug discovery: where are we now? Nat. Rev. Drug Discov. 12, 644-645 (2013
23. Hall, R. J., Mortenson, P. N., & Murray, C. W. Efficient exploration of chemical space by fragment-based screening. Prog. Biophys. Mol. Biol. 116, 82-91 (2014
24. Hajduk, P. J., Bures, M., Praestgaard, J., & Fesik, S. W. Privileged molecules for protein binding identified from NMR-based screening. J. Med. Chem. 43, 3443-3447 (2000
25. Hajduk, P. J., et al. NMR-based screening of proteins containing 13C labeled methyl groups. J. Am. Chem. Soc. 122, 7898-7904 (2000
26. Erlanson, D. A. in Fragment-based Drug Discovery. Vol. 47 (eds Howard, S., & Abell, C.) 19-30 (Royal Society of Chemistry, 2015
27. Friberg, A., et al. Discovery of potent myeloid cell leukemia 1 (Mcl 1) inhibitors using fragment-based methods and structure-based design. J. Med. Chem. 56, 15-30 (2013
28. Davis, B. J., & Erlanson, D. A. Learning from our mistakes: the ?unknown knowns? in fragment screening. Bioorg. Med. Chem. Lett. 23, 2844-2852 (2013
29. Dalvit, C., Caronni, D., Mongelli, N., Veronesi, M., & Vulpetti, A. NMR-based quality control approach for the identification of false positives and false negatives in high throughput screening. Curr. Drug Discov. Technol. 3, 115-124 (2006
30. Huth, J. R., et al. ALARM NMR: a rapid and robust experimental method to detect reactive false positives in biochemical screens. J. Am. Chem. Soc. 127, 217-224 (2005
31. Baell, J. B., & Holloway, G. A. New substructure filters for removal of pan assay interference compounds (PAINS) from screening libraries and for their exclusion in bioassays. J. Med. Chem. 53, 2719-2740 (2010
32. Baell, J. B. Observations on screening-based research and some concerning trends in the literature. Future Med. Chem. 2, 1529-1546 (2010
33. Baell, J., & Walters, M. A. Chemistry: chemical con artists foil drug discovery. Nature 513, 481-483 (2014
34. Seidler, J., McGovern, S. L., Doman, T. N., & Shoichet, B. K. Identification and prediction of promiscuous aggregating inhibitors among known drugs. J. Med. Chem. 46, 4477-4486 (2003
35. Feng, B. Y., Shelat, A., Doman, T. N., Guy, R. K., & Shoichet, B. K. High-Throughput assays for promiscuous inhibitors. Nat. Chem. Biol. 1, 146-148 (2005
36. Morley, A. D., et al. Fragment-based hit identification: thinking in 3D. Drug Discov. Today 18, 1221-1227 (2013
37. Davies, D. R., et al. Discovery of leukotriene A4 hydrolase inhibitors using metabolomics biased fragment crystallography. J. Med. Chem. 52, 4694-4715 (2009
38. Over, B., et al. Natural-product-derived fragments for fragment-based ligand discovery. Nat. Chem. 5, 21-28 (2013
39. Vulpetti, A., & Dalvit, C. Design and generation of highly diverse fluorinated fragment libraries and their efficient screening with improved 19F NMR methodology. ChemMedChem. 8, 2057-2069 (2013
40. Akritopoulou-Zanze, I., & Hajduk, P. J. Kinase-Targeted libraries: the design and synthesis of novel, potent, and selective kinase inhibitors. Drug Discov. Today 14, 291-297 (2009
41. Ostermann, N., et al. A novel class of oral direct renin inhibitors: highly potent 3, 5 disubstituted piperidines bearing a tricyclic p3 p1 pharmacophore. J. Med. Chem. 56, 2196-2206 (2013
42. Rüdisser, S., Vangrevelinghe, E., & Maibaum, J. in Fragment-based Drug Discovery: Lessons and Outlook. Vol. 67 (eds Erlanson, D. A., & Jahnke, W.) 447-486 (Wiley-VCH, 2016
43. Lepre, C. A. Practical aspects of NMR-based fragment screening. Methods Enzymol. 493, 219-239 (2011
44. Stockman, B. J., & Dalvit, C. NMR screening techniques in drug discovery and drug design. Prog. Nucl. Mag. Res. Spectrosc. 41, 183-231 (2002
45. Cala, O., & Krimm, I. Ligand-orientation based fragment selection in STD NMR screening. J. Med. Chem. 58, 8739-8742 (2015
46. Dalvit, C., Fagerness, P. E., Hadden, D. T., Sarver, R. W., & Stockman, B. J. Fluorine-NMR experiments for high-Throughput screening: theoretical aspects, practical considerations, and range of applicability. J. Am. Chem. Soc. 125, 7696-7703 (2003
47. Giannetti, A. M. From experimental design to validated hits a comprehensive walk-Through of fragment lead identification using surface plasmon resonance. Methods Enzymol. 493, 169-218 (2011
48. Danielson, U. H. Integrating surface plasmon resonance biosensor-based interaction kinetic analyses into the lead discovery and optimization process. Future Med. Chem. 1, 1399-1414 (2009
49. Jhoti, H., Cleasby, A., Verdonk, M., & Williams, G. Fragment-based screening using X ray crystallography and NMR spectroscopy. Curr. Opin. Chem. Biol. 11, 485-493 (2007
50. Schiebel, J., et al. Six biophysical screening methods miss a large proportion of crystallographically discovered fragment hits: a case study. ACS Chem. Biol. 11, 1693-1701 (2016
51. Davies, T. G., et al. Monoacidic inhibitors of the Kelch-like ECH-Associated protein 1: nuclear factor erythroid 2-related factor 2 (KEAP1:NRF2) protein-protein interaction with high cell potency identified by fragment-based discovery. J. Med. Chem. 59, 3991-4006 (2016
52. Hartshorn, M. J., et al. Fragment-based lead discovery using X ray crystallography. J. Med. Chem. 48, 403-413 (2005
53. Koh, C. Y., et al. A binding hotspot in Trypanosoma cruzi histidyl-TRNA synthetase revealed by fragment-based crystallographic cocktail screens. Acta Crystallogr. D Biol. Crystallogr. 71, 1684-1698 (2015
54. Mashalidis, E. H., Sledz, P., Lang, S., & Abell, C. A three-stage biophysical screening cascade for fragment-based drug discovery. Nat. Prot. 8, 2309-2324 (2013
55. Scott, D. E., Spry, C., & Abell, C. in Fragment-based drug discovery: Lessons and outlook (eds Erlanson, D. A., & Jahnke, W.) 139-172 (Wiley-VCH, 2016
56. Jerabek-Willemsen, M., Wienken, C. J., Braun, D., Baaske, P., & Duhr, S. Molecular interaction studies using microscale thermophoresis. Assay Drug Dev. Technol. 9, 342-353 (2011
57. Meiby, E., et al. Fragment screening by weak affinity chromatography: comparison with established techniques for screening against HSP90. Anal. Chem. 85, 6756-6766 (2013
58. Wielens, J., et al. Parallel screening of low molecular weight fragment libraries: do differences in methodology affect hit identification? J. Biomol. Screen. 18, 147-159 (2013
59. Schiebel, J., et al. One question, multiple answers: biochemical and biophysical screening methods retrieve deviating fragment hit lists. ChemMedChem. 10, 1511-1521 (2015
60. Kutchukian, P. S., et al. Large scale meta-Analysis of fragment-based screening campaigns: privileged fragments and complementary technologies. J. Biomol. Screen. 20, 588-596 (2015
61. Ludlow, R. F., Verdonk, M. L., Saini, H. K., Tickle, I. J., & Jhoti, H. Detection of secondary binding sites in proteins using fragment screening. Proc. Nat. Acad. Sci. USA 112, 15910-15915 (2015
62. Murray, C. W., Verdonk, M. L., & Rees, D. C. Experiences in fragment-based drug discovery. Trends Pharmacol. Sci. 33, 224-232 (2012
63. Hopkins, A. L., Groom, C. R., & Alex, A. Ligand efficiency: a useful metric for lead selection. Drug Discov. Today 9, 430-431 (2004
64. Hopkins, A. L., Keseru, G. M., Leeson, P. D., Rees, D. C., & Reynolds, C. H. The role of ligand efficiency metrics in drug discovery. Nat. Rev. Drug Discov. 13, 105-121 (2014
65. Bamborough, P., Brown, M. J., Christopher, J. A., Chung, C. W., & Mellor, G. W. Selectivity of kinase inhibitor fragments. J. Med. Chem. 54, 5131-5143 (2011
66. Allen, C., Welford, A., Matthews, T., Caldwell, J., & Collins, I. Fragment growing to retain or alter the selectivity of anchored kinase hinge-binding fragments. Med. Chem. Commun. 5, 180-185 (2014
67. Woolford, A. J. Experiences with fragment libraries at Astex. Presented at the Fragment-based Lead Discovery (FBLD) Conference. (2014
68. Hubbard, R. E. in Fragment-based Drug Discovery: Lessons and Outlook. Vol. 67 (eds Erlanson, D. A., & Jahnke, W.) 3-36 (Wiley-VCH, 2016
69. Devine, S. M., et al. Promiscuous 2 aminothiazoles (PrATs): a frequent hitting scaffold. J. Med. Chem. 58, 1205-1214 (2015
70. Bauman, J. D., Harrison, J. J., & Arnold, E. Rapid experimental SAD phasing and hot-spot identification with halogenated fragments. IUCrJ 3, 51-60 (2016
71. Bauman, J. D., et al. Detecting allosteric sites of HIV 1 reverse transcriptase by X ray crystallographic fragment screening. J. Med. Chem. 56, 2738-2746 (2013
72. Kozakov, D., et al. Ligand deconstruction: why some fragment binding positions are conserved and others are not. Proc. Nat. Acad. Sci. USA 112, E2585-E2594 (2015
73. Saalau-Bethell, S. M., et al. Discovery of an allosteric mechanism for the regulation of HCV NS3 protein function. Nat. Chem. Biol. 8, 920-925 (2012
74. Murray, J., et al. Tailoring small molecules for an allosteric site on procaspase 6. ChemMedChem. 9, 73-77 (2014
75. Hajduk, P. J., Huth, J. R., & Fesik, S. W. Druggability indices for protein targets derived from NMR-based screening data. J. Med. Chem. 48, 2518-2525 (2005
76. Chen, I. J., & Hubbard, R. E. Lessons for fragment library design: analysis of output from multiple screening campaigns. J. Comput. Aided Mol. Des. 23, 603-620 (2009
77. Lau, W. F., et al. Design of a multi-purpose fragment screening library using molecular complexity and orthogonal diversity metrics. J. Comput. Aided Mol. Des. 25, 621-636 (2011
78. Borsi, V., Calderone, V., Fragai, M., Luchinat, C., & Sarti, N. Entropic contribution to the linking coefficient in fragment based drug design: a case study. J. Med. Chem. 53, 4285-4289 (2010
79. Ichihara, O., Barker, J., Law, R. J., & Whittaker, M. Compound design by fragment-linking. Mol. Informat. 30, 298-306 (2011
80. Ward, R. A., et al. Design and synthesis of novel lactate dehydrogenase a inhibitors by fragment-based lead generation. J. Med. Chem. 55, 3285-3306 (2012
81. Korczynska, M., et al. Docking and linking of fragments to discover jumonji histone demethylase inhibitors. J. Med. Chem. 59, 1580-1598 (2016
82. Czaplewski, L. G., et al. Antibacterial alkoxybenzamide inhibitors of the essential bacterial cell division protein FtsZ. Bioorg. Med. Chem. Lett. 19, 524-527 (2009
83. Murray, C. W., & Rees, D. C. Opportunity knocks: organic chemistry for fragment-based drug discovery (FBDD). Angew. Chem. Int. 55, 488-492 (2016
84. Bollag, G., et al. Vemurafenib: the first drug approved for BRAF-mutant cancer. Nat. Rev. Drug Discov. 11, 873-886 (2012
85. Addie, M., et al. Discovery of 4 amino N-[(1S)-1-(4 chlorophenyl)-3 hydroxypropyl]-1-(7H pyrrolo[2, 3 d]pyrimidin-4 yl)piperidine 4 carboxamide (AZD5363), an orally bioavailable, potent inhibitor of Akt kinases. J. Med. Chem. 56, 2059-2073 (2013
86. Caldwell, J. J., et al. Identification of 4-(4 aminopiperidin 1 yl)-7H pyrrolo[2, 3 d]pyrimidines as selective inhibitors of protein kinase B through fragment elaboration. J. Med. Chem. 51, 2147-2157 (2008
87. Albert, J. S., et al. An integrated approach to fragment-based lead generation: philosophy, strategy and case studies from AstraZeneca?s drug discovery programmes. Curr. Top. Med. Chem. 7, 1600-1629 (2007
88. de Graaf, C., et al. Small and colorful stones make beautiful mosaics: fragment-based chemogenomics. Drug Discov. Today 18, 323-330 (2013
89. Rasmussen, S. G., et al. Crystal structure of the human β2 adrenergic G protein-coupled receptor. Nature 450, 383-387 (2007
90. Warne, T., et al. Structure of a β1 adrenergic G protein-coupled receptor. Nature 454, 486-491 (2008
91. Christopher, J. A., et al. Biophysical fragment screening of the β1 adrenergic receptor: identification of high affinity arylpiperazine leads using structure-based drug design. J. Med. Chem. 56, 3446-3455 (2013
92. Wolkenberg, S. E., et al. High concentration electrophysiology-based fragment screen: discovery of novel acid-sensing ion channel 3 (ASIC3) inhibitors. Bioorg. Med. Chem. Lett. 21, 2646-2649 (2011
93. Szollosi, E., et al. Cell-based and virtual fragment screening for adrenergic α2C receptor agonists. Bioorg. Med. Chem. 23, 3991-3999 (2015
94. Oltersdorf, T., et al. An inhibitor of Bcl 2 family proteins induces regression of solid tumours. Nature 435, 677-681 (2005
95. Souers, A. J., et al. ABT 199, a potent and selective BCL 2 inhibitor, achieves antitumor activity while sparing platelets. Nat. Med. 19, 202-208 (2013
96. Petros, A. M., et al. Fragment-based discovery of potent inhibitors of the anti-Apoptotic MCL 1 protein. Bioorg. Med. Chem. Lett. 24, 1484-1488 (2014
97. Burke, J. P., et al. Discovery of tricyclic indoles that potently inhibit Mcl 1 using fragment-based methods and structure-based design. J. Med. Chem. 58, 3794-3805 (2015
98. Maurer, T., et al. Small-molecule ligands bind to a distinct pocket in Ras and inhibit SOS-mediated nucleotide exchange activity. Proc. Nat. Acad. Sci. USA 109, 5299-5304 (2012
99. Sun, Q., et al. Discovery of small molecules that bind to K Ras and inhibit Sos-mediated activation. Angew. Chem. Int. Ed. 51, 6140-6143 (2012
100. Ostrem, J. M., Peters, U., Sos, M. L., Wells, J. A., & Shokat, K. M. K Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions. Nature 503, 548-551 (2013
101. Winter, J. J., et al. Small molecule binding sites on the Ras:SOS complex can be exploited for inhibition of Ras activation. J. Med. Chem. 58, 2265-2274 (2015
102. Patricelli, M. P., et al. Selective inhibition of oncogenic KRAS output with small molecules targeting the inactive state. Cancer Discov. 6, 316-329 (2016
103. Darby, J. F., et al. Discovery of selective small-molecule activators of a bacterial glycoside hydrolase. Angew. Chem. Int. Ed. 53, 13419-13423 (2014
104. Jahnke, W., et al. Binding or bending: distinction of allosteric Abl kinase agonists from antagonists by an NMR-based conformational assay. J. Am. Chem. Soc. 132, 7043-7048 (2010
105. Davies, T. G., Jhoti, H., Pathuri, P., & Williams, G. in Fragment-based Drug Discovery: Lessons and Outlook. Vol. 67 (eds Erlanson, D. A., & Jahnke, W.) 37-56 (Wiley-VCH, 2016
106. Folmer, R. H. Integrating biophysics with HTS-driven drug discovery projects. Drug Discov. Today 21, 491-498 (2016
107. Whittaker, M. Picking up the pieces with FBDD or FADD: invest early for future success. Drug Discov. Today 14, 623-624 (2009
108. Taylor, S. J., et al. Discovery of potent, selective chymase inhibitors via fragment linking strategies. J. Med. Chem. 56, 4465-4481 (2013
109. Palmer, N., Peakman, T. M., Norton, D., & Rees, D. C. Design and synthesis of dihydroisoquinolones for fragment-based drug discovery (FBDD).org. Biomol. Chem. 14, 1599-1610 (2016
110. Murray, J. B., Roughley, S. D., Matassova, N., & Brough, P. A. Off-rate screening (ORS) by surface plasmon resonance. An efficient method to kinetically sample hit to lead chemical space from unpurified reaction products. J. Med. Chem. 57, 2845-2850 (2014